The present invention provides a pharmaceutical composition comprising an LRP1 receptor agonist for use in the treatment of cancer characterized by an up-regulated or constitutively active Wnt signaling pathway and a method for identifying LRP1 receptor agonists suitable as therapeutic agents for treating such cancers. The present invention also provides a pharmaceutical composition comprising an LRP1 receptor agonist for use in the treatment of an HIV-infection. Furthermore, the present invention relates to the therapeutic use of LRP1 receptor agonists and a kit of parts comprising the pharmaceutical composition according to the invention.
